{"links":{"feed":"https://www.erudio.com/reports/cyclone-3-nct05288166/feed.json","html":"https://www.erudio.com/reports/cyclone-3-nct05288166","json":"https://www.erudio.com/reports/cyclone-3-nct05288166.json","markdown":"https://www.erudio.com/reports/cyclone-3-nct05288166.md","mcp":{"server":"https://mcp.erudio.com/free","tool":"get_report_card","arguments":{"slug":"cyclone-3-nct05288166"}},"request":"https://www.erudio.com/contact?report=cyclone-3-nct05288166"},"offer":{"cited_clinicians":11,"cited_commentary_sources":14,"verified_hcp_statements":218,"currency":"USD","delivery":{"checkout":"online","current_edition":"Emailed as soon as payment clears: downloads, a license key and a prompt that connects your AI agent through Erudio MCP. One key per email address holds every report bought with it.","refresh":"A purchase starts a check for new commentary. A new edition, if one results, is sent to the buyer at no charge."},"verified_ids":{"included":"Every product, the free report included, comes with verified IDs for each identity-checked speaker (the NPI, ORCID and OpenAlex IDs, and their institution's staff page), so your team can check each attribution itself, inline on each person card under identifiers. Social accounts (X, Bluesky, LinkedIn) are not included. For checking attribution inside the organization. Allowed: advisory boards, scientific exchange and finding investigators, under your own compliance process. Not allowed: sales or marketing to clinicians. Sample: https://www.erudio.com/report-sample.json","identity_verified_people":13},"for_sale":true,"one_off_usd":1250,"purchase":{"agents":{"free_mcp":"https://mcp.erudio.com/free","keys":"One license key holds every report: get_order returns it once paid (store it as a secret), send it as licence_key with every later create_order so new reports join it. The buyer gets their account key by email, which reads every report bought with their address; recover_key (POST /api/keys/recover) with the buyer's email sends it again.","mcp_flow":["1. search_reports: Find reports by trial, NCT ID, drug, indication or sponsor. Each result has its page URL and price.","2. get_report_card: Preview one report with the slug from search_reports: what it covers, its findings and limits, and the price of each product.","3. create_order: Order the current edition or 3, 6 or 12 months of updates for your person; ask them for their work email and organization, both required. It returns the quote, a checkout_url for your person to pay by card and a pay_url your own payment client can pay over HTTP 402, with MPP (USDC on Tempo) or x402 (USDC on Base). Nothing is charged until one is paid.","4. get_order: Once the order is paid, it returns the license key. Store the key as a secret and send it as licence_key with every later create_order, so one key holds every report.","5. read_report: Read the report in full or by section on https://mcp.erudio.com/mcp, with the key as Authorization: Bearer. get_report_changes shows what a newer edition changed."],"order_endpoint":"https://www.erudio.com/api/orders","order_request":{"buyer_email":"name@company.com","idempotency_key":"optional, one per purchase","licence_key":"optional: your key from an earlier purchase","organization":"required: the buyer's company or institution","product":["edition","updates-3","updates-6","updates-12"],"report":"cyclone-3-nct05288166"},"steps":"Create the order (with licence_key if you hold one) and show checkout_url to your person to pay by card. Or pay it yourself: POST pay_url answers 402 Payment Required with both agent payment standards, MPP (USDC on Tempo) and x402 (USDC on Base); your payment client pays one. Once paid, status_url (or get_order) returns the license key, the MCP setup and downloads."},"contact":{"email":"hello@erudio.com","form":"https://www.erudio.com/contact?report=cyclone-3-nct05288166","people":"Audun Utengen and Tom Lee, the founders","use_for":"Questions, invoices, purchase orders"},"methods":["card (Stripe Checkout)"],"people":"https://www.erudio.com/reports/cyclone-3-nct05288166","renewal":"Subscriptions are prepaid, and the price is fixed for the term you buy, even if a new edition moves the trial up a size. Nothing renews automatically: a new term is bought at the price then current.","upgrades":"What the buyer already paid on this trial counts toward a longer plan: a one-off edition within 30 days, or an active plan at any time in its term. The buyer pays the difference; an upgraded plan keeps its original start, and an upgraded one-off starts the plan on payment. Order the longer product with create_order and the buyer's licence_key (or on the report page with the buyer's email); the quote shows the credit.","terms":"https://www.erudio.com/terms"},"size":"standard","size_line":"Standard · 218 verified statements · 54 from 11 confirmed clinicians","size_rule":"Standard: 151–300 verified statements. Standard and Deep need 5 or more confirmed clinicians cited (role verified by the NPI registry or their own institution's staff page); otherwise a report is Focused.","updates_usd":{"3_months":2200,"6_months":3100,"12_months":4400},"volume_discounts":{"applies_to":"Update plans (updates-3, updates-6, updates-12) only. Never a single edition (product edition), however many an account buys.","rule":"Volume discounts apply to update plans only: 15% off a plan when one account has update plans on 5 or more trials, 25% off from 10 or more. A single edition is never discounted, however many an account buys, and there are no other discounts.","tiers":[{"min_subscribed_trials":10,"percent_off_updates":25},{"min_subscribed_trials":5,"percent_off_updates":15}]}},"publication_state":"public","record":{"change":{"changed_finding_ids":{"reason":"No changed finding IDs recorded.","status":"none"},"last_checked_at":"2026-11-17T00:14:56.577694Z","notify_subscribers":false,"status":"corrected","summary":"taxonomy mapping corrected"},"contents":{"aspect_coverage":{"assessment_incomplete":0,"discussed":14,"no_commentary_found":0},"aspects":[{"claim_count":3,"coverage":"discussed","id":"T1","registry_field":"outcomesModule.primaryOutcomes[0]","source_count":3,"title":"Primary endpoint: Radiographic Progression-Free Survival (rPFS) Assessed by Investigator"},{"claim_count":2,"coverage":"discussed","id":"T2","registry_field":"outcomesModule.secondaryOutcomes","source_count":2,"title":"Secondary endpoints"},{"claim_count":8,"coverage":"discussed","id":"T3","registry_field":"conditionsModule","source_count":4,"title":"Population and setting"},{"claim_count":7,"coverage":"discussed","id":"T4","registry_field":"armsInterventionsModule.armGroups","source_count":5,"title":"The comparison"},{"claim_count":8,"coverage":"discussed","id":"T5","registry_field":"armsInterventionsModule.interventions","source_count":2,"title":"Safety and tolerability"},{"claim_count":7,"coverage":"discussed","id":"T6","registry_field":"designModule","source_count":4,"title":"Design and conduct"},{"claim_count":18,"coverage":"discussed","id":"A1","source_count":7,"title":"Biological rationale and uncertainty about clinical translation"},{"claim_count":29,"coverage":"discussed","id":"A2","source_count":4,"title":"Doublet versus chemotherapy-containing triplet selection"},{"claim_count":12,"coverage":"discussed","id":"A3","source_count":2,"title":"Disease-site heterogeneity, imaging and diagnostic certainty"},{"claim_count":26,"coverage":"discussed","id":"A4","source_count":4,"title":"Hormonal-partner choice, cardiovascular coordination and access"},{"claim_count":23,"coverage":"discussed","id":"A5","source_count":8,"title":"Genetic work-up, prognostic information and patient support"},{"claim_count":14,"coverage":"discussed","id":"A6","source_count":3,"title":"Prostate-directed radiation, urinary morbidity and referral timing"},{"claim_count":13,"coverage":"discussed","id":"A7","source_count":3,"title":"Downstream treatment applicability and aggressive progression"},{"claim_count":19,"coverage":"discussed","id":"A8","source_count":4,"title":"Implementation, uncommon monotherapy exceptions and cautious ADT interruption"}],"counts":{"beyond_population_findings":8,"beyond_population_statements":114,"cited_clinicians":11,"cited_clinicians_by_role":{"physician":3,"physician, Medical oncology":6,"physician, Surgical oncology":1,"physician, Urology":1},"cited_physicians":11,"cited_sources":15,"claims_by_expression_type":{"comparison":8,"experience":33,"interpretation":34,"opinion":69,"primary_context":8,"question":16,"restatement":19,"uncertainty":16,"unspecified":15},"claims_by_kind":{"protocol_statement":8,"source_observation":210},"clinician_statements":54,"evidence_units":136,"findings":11,"organisational_accounts":2,"people_cited":14,"people_identity_verified":13,"people_total":14,"screened_sources":41,"verified_claims":218},"findings_index":[{"cited_clinicians":1,"id":"F1","structure":{"claims":12,"claims_by_group":{"comparisons":0,"experience":0,"questions":3,"restated":1,"views":8},"limitations":3,"links":{"context":8,"support":12},"ma_question":true,"named_voices":2,"passages":15,"sources":8,"sources_by_kind":{"commentary":2,"media":5,"registry":1}},"title":"CDK4/6–AR rationale: why speakers see prostate cancer benefit as an open question","title_holders":{"cited_claim_ids":["claim-248afe9af9f47b60d0cd","claim-0e25d6ae85a15002f9dc","claim-de87a7e0b4af17316ee5","claim-f570d0bdbb777b16af00","claim-ae71cff6189225976a0a","claim-4ce77820453ba2fc99fc","claim-dd556761416b3f07b96a"],"clinicians":false,"holders":2,"speakers":2,"view":"reading"},"evidence_line":"12 statements from 2 speakers in 8 sources, 5 of them podcasts or videos","holder_line":"2 of the 2 named speakers in this finding hold this view"},{"cited_clinicians":0,"id":"F2","structure":{"claims":2,"claims_by_group":{"comparisons":0,"experience":0,"questions":1,"restated":1,"views":0},"limitations":2,"links":{"context":1,"support":2},"ma_question":true,"named_voices":0,"passages":2,"sources":2,"sources_by_kind":{"media":1,"registry":1}},"title":"CDK4/6 in prostate cancer: what speakers say","evidence_line":"2 statements in 2 sources, 1 of them a podcast or video"},{"cited_clinicians":1,"id":"F3","structure":{"claims":10,"claims_by_group":{"comparisons":0,"experience":1,"questions":0,"restated":4,"views":5},"limitations":3,"links":{"context":6,"support":12},"ma_question":true,"named_voices":3,"passages":13,"sources":6,"sources_by_kind":{"commentary":2,"media":3,"registry":1}},"title":"CYCLONE 3: what speakers say","evidence_line":"10 statements from 3 speakers in 6 sources, 3 of them podcasts or videos"},{"cited_clinicians":3,"id":"F4","population":"beyond","structure":{"claims":18,"claims_by_group":{"comparisons":1,"experience":2,"questions":4,"restated":1,"views":10},"limitations":4,"links":{"context":3,"support":20},"ma_question":true,"named_voices":3,"passages":15,"sources":3,"sources_by_kind":{"media":3}},"title":"Triplets: what speakers say","evidence_line":"18 statements from 3 speakers in 3 sources, all podcasts or videos"},{"cited_clinicians":0,"id":"F5","population":"beyond","structure":{"claims":11,"claims_by_group":{"comparisons":0,"experience":3,"questions":2,"restated":2,"views":4},"limitations":3,"links":{"context":4,"support":13},"ma_question":true,"named_voices":0,"passages":7,"sources":2,"sources_by_kind":{"media":1,"registry":1}},"title":"This lung-only relapse: what speakers say","evidence_line":"11 statements in 2 sources, 1 of them a podcast or video"},{"cited_clinicians":3,"id":"F6","population":"beyond","structure":{"claims":11,"claims_by_group":{"comparisons":0,"experience":2,"questions":0,"restated":2,"views":7},"limitations":4,"links":{"context":2,"support":14},"ma_question":true,"named_voices":3,"passages":10,"sources":3,"sources_by_kind":{"media":3}},"title":"MHSPC: most clinicians usually escalate when apt—one rarely holds ADT for harm","title_holders":{"caveat":{"among_lead":true,"cited_claim_ids":["claim-b7a50b6def5c858dca16"],"clause":"one rarely holds ADT for harm","holders":1},"cited_claim_ids":["claim-1c2eb07a110ebc057440","claim-4e9d49790cce54910210","claim-7cbf9c0a064b0ba1ff14","claim-4dc3767b1a62eed644cd","claim-8e8bc0ade5bd4f342064"],"clinicians":true,"holders":2,"speakers":3,"view":"reading"},"evidence_line":"11 statements from 3 speakers in 3 sources, all podcasts or videos","holder_line":"2 of the 3 named speakers in this finding hold this view, each a confirmed clinician; 1 of them holds its caveat, “one rarely holds ADT for harm”"},{"cited_clinicians":2,"id":"F7","population":"beyond","structure":{"claims":19,"claims_by_group":{"comparisons":2,"experience":8,"questions":2,"restated":1,"views":6},"limitations":4,"links":{"context":3,"support":19},"ma_question":true,"named_voices":2,"passages":9,"sources":4,"sources_by_kind":{"media":4}},"title":"Hormonal partners: how clinicians weigh tolerability, comorbidity and cost","title_holders":{"cited_claim_ids":["claim-262503f16b03d222304b","claim-2e1068ec5bd084af406e","claim-15666afefbdb041e6349","claim-731b3016f8190d33ec1b","claim-cd7b7b9d059cda55df60","claim-29308ed98e99448d4400","claim-3ad2bef70031d4228cb3","claim-5221416735a1e7aefcb4","claim-34f20a56e474f46535ff","claim-707d39e4870626d87053","claim-0cc1361e0c60c5b9c673","claim-ac554a5b6f0bf5cf8c99","claim-10357e6d8ed44770166d","claim-2d52e4ebaa53166663e8","claim-d77404c6e7f0bb401c66","claim-ba8941459abf3431e8e8"],"clinicians":true,"holders":2,"speakers":2,"view":"reading"},"evidence_line":"19 statements from 2 speakers in 4 sources, all podcasts or videos","holder_line":"2 of the 2 named speakers in this finding hold this view, each a confirmed clinician"},{"cited_clinicians":2,"id":"F8","population":"beyond","structure":{"claims":7,"claims_by_group":{"comparisons":0,"experience":1,"questions":2,"restated":1,"views":3},"limitations":3,"links":{"context":1,"support":7},"ma_question":true,"named_voices":2,"passages":4,"sources":3,"sources_by_kind":{"media":3}},"title":"Chemo-free darolutamide: a clinician seeks selective access—one awaits data","title_holders":{"caveat":{"among_lead":true,"cited_claim_ids":["claim-6584e87bf5ecf1c47926"],"clause":"one awaits data","holders":1},"cited_claim_ids":["claim-dd2b0fc88fdeaff4dcf9","claim-597463909f39d63a81e2","claim-2f0baa1ef5d7190d7121"],"clinicians":true,"holders":1,"speakers":2,"view":"reading"},"evidence_line":"7 statements from 2 speakers in 3 sources, all podcasts or videos","holder_line":"1 of the 2 named speakers in this finding holds this view, a confirmed clinician; 1 of them holds its caveat, “one awaits data”"},{"cited_clinicians":4,"id":"F9","population":"beyond","structure":{"claims":23,"claims_by_group":{"comparisons":0,"experience":6,"questions":3,"restated":6,"views":8},"limitations":3,"links":{"context":2,"support":24},"ma_question":true,"named_voices":5,"passages":19,"sources":8,"sources_by_kind":{"commentary":4,"media":4}},"title":"Genetic work-up: what speakers say","evidence_line":"23 statements from 5 speakers in 8 sources, 4 of them podcasts or videos"},{"cited_clinicians":3,"id":"F10","population":"beyond","structure":{"claims":15,"claims_by_group":{"comparisons":0,"experience":3,"questions":2,"restated":1,"views":9},"limitations":4,"links":{"context":2,"support":15},"ma_question":true,"named_voices":3,"passages":11,"sources":4,"sources_by_kind":{"media":3,"registry":1}},"title":"PEACE-1 prostate RT: what speakers say","evidence_line":"15 statements from 3 speakers in 4 sources, 3 of them podcasts or videos"},{"cited_clinicians":2,"id":"F11","population":"beyond","structure":{"claims":13,"claims_by_group":{"comparisons":0,"experience":2,"questions":2,"restated":3,"views":6},"limitations":4,"links":{"context":1,"support":13},"ma_question":true,"named_voices":2,"passages":11,"sources":3,"sources_by_kind":{"media":3}},"title":"Hard de novo doublet/triplet cases: a clinician weighs chance in a neuroendocrine rise","title_holders":{"cited_claim_ids":["claim-0404e2803b7d34149a1a"],"clinicians":true,"holders":1,"speakers":2,"view":"reading"},"evidence_line":"13 statements from 2 speakers in 3 sources, all podcasts or videos","holder_line":"1 of the 2 named speakers in this finding holds this view, a confirmed clinician"}],"open_question":{"basis":"From finding F1 (12 statements from 2 speakers in 8 sources)","cited_claim_ids":["claim-53b6a7c5920392cec097","claim-2d68289fa356b0c80b59","claim-248afe9af9f47b60d0cd","claim-0e25d6ae85a15002f9dc","claim-de87a7e0b4af17316ee5","claim-f570d0bdbb777b16af00","claim-f12f96c2e304b50d3e8b","claim-ae71cff6189225976a0a","claim-4ce77820453ba2fc99fc","claim-dd556761416b3f07b96a","claim-2ed661cf29be04efbfc3","claim-eb5e2dd055554841d901"],"finding_ids":["F1"],"question":"What do clinicians still need to see in CYCLONE 3 to establish whether adding abemaciclib to abiraterone translates the CDK4/6–androgen receptor rationale into clinical benefit in high-risk metastatic hormone-sensitive prostate cancer?"},"sections":{"analysis":[{"id":"section-1","level":2,"title":"Whether the CDK4/6–AR pathway rationale would translate into clinical benefit"},{"id":"section-2","level":2,"title":"One panel episode raised gastrointestinal and hematologic concerns while withholding a risk–benefit judgment"},{"id":"section-3","level":2,"title":"One panel episode linked global conduct and timely completion to a rapidly changing treatment landscape"},{"id":"section-4","level":2,"title":"Beyond the trial population"},{"id":"section-5","level":3,"title":"Whether immediate docetaxel improved on an ADT–AR-pathway doublet remained open in the discussions"},{"id":"section-6","level":3,"title":"One episode treats lung-only visceral relapse as a reason not to intensify automatically with chemotherapy"},{"id":"section-7","level":3,"title":"Clinicians favored AR-pathway intensification; one clinician described rare reasons to interrupt treatment"},{"id":"section-8","level":3,"title":"Clinicians make abiraterone selection conditional on tolerability, comorbidity and cost"},{"id":"section-9","level":3,"title":"Whether chemotherapy-free darolutamide is justified despite evidence and access limits"},{"id":"section-10","level":3,"title":"One clinician describes early genetic work-up; discussions detail testing and support barriers"},{"id":"section-11","level":3,"title":"Whether prostate radiation added survival value alongside intensified systemic treatment"},{"id":"section-12","level":3,"title":"One clinician qualified a perceived neuroendocrine increase as possibly personal bad luck"},{"id":"section-13","level":2,"title":"Scope and coverage"}],"executive_summary":{"reason":"Reviewed narrative has no headings.","status":"unavailable"}},"study_design":"interventional, randomized, parallel, phase3","trial_dimensions":[{"findings":[{"id":"F3","shared_claims":2}],"id":"T1","label":"Primary endpoint: Radiographic Progression-Free Survival (rPFS) Assessed by Investigator"},{"findings":[{"id":"F3","shared_claims":1}],"id":"T2","label":"Secondary endpoints"},{"findings":[{"id":"F1","shared_claims":1},{"id":"F3","shared_claims":2}],"id":"T3","label":"Population and setting"},{"findings":[{"id":"F1","shared_claims":1},{"id":"F3","shared_claims":2}],"id":"T4","label":"The comparison"},{"findings":[{"id":"F2","shared_claims":1}],"id":"T5","label":"Safety and tolerability"},{"findings":[{"id":"F3","shared_claims":7}],"id":"T6","label":"Design and conduct"}]},"identity":{"accepted_at":"2026-11-17T00:14:56.577694Z","edition_number":1,"previous_run_id":{"reason":"First accepted catalog edition.","status":"not_applicable"},"previous_version":{"reason":"First accepted catalog edition.","status":"not_applicable"},"product_contract":"hcp-commentary-1","published_at":"2026-11-17T08:18:16Z","record_hash":"e8aeb4522d0fe5529e2cab302af55136bda17c92d00e1c1c3ef5aade81334203","release_hash":"92ea8f640bfc4e3e319463c5000c1c8774c959c9b72f58e5461219d903f8ac0b","report_id":"erudio-nct05288166","run_id":"a58a68e2-6f88-409c-8e1f-3415daadeedd","schema_version":"5.0","slug":"cyclone-3-nct05288166","version":"1.0.0","version_reason":"initial"},"offer":{"bundle_eligible":{"reason":"Owner has not set bundle_eligible.","status":"not_set"},"license_ref":{"reason":"Owner has not set license_ref.","status":"not_set"},"request_route":{"reason":"Owner has not set request_route.","status":"not_set"},"single_edition":{"reason":"Owner has not set single_edition.","status":"not_set"},"updates":{"reason":"Owner has not set updates.","status":"not_set"}},"preview":{"abstract":"For CYCLONE 3, a medical oncologist considered benefit less likely after reporting a CYCLONE-2 setback in castration-resistant disease, but left the answer to trials then underway. Gastrointestinal effects and low blood counts were raised in one discussion without a risk–benefit verdict. The cited commentary does not address the posted results, leaving clinicians’ interpretation of those results unknown.","examples":[],"meta_description":"41 sources screened · 218 verified statements (54 from clinicians verified by NPI or staff page) from 15 sources · 11 findings. Updated Nov 17, 2026.","person_names_policy":"role_only"},"publication":{"approved_at":"2026-11-17T08:18:16Z","approved_by":"Erudio publisher","corrections":[{"affected_ids":[],"date":"2026-11-17T20:19:55Z","kind":"routine","summary":"taxonomy mapping corrected"}],"rights_status":"cleared: short attributed excerpts with link-out; no-derivatives sources suppressed; role-only names in previews","state":"public"},"schema_id":"erudio.catalog_record","schema_version":"2.1","scope_and_limits":{"commentary_scope":{"basis":"Only the sources used in this report; not all HCPs or all public discussion.","has_known_gaps":true,"source_count":41},"does_not":["judge efficacy","estimate HCP prevalence or consensus","give treatment advice"],"known_gaps":["Discussion that does not name the trial may be missing from this edition.","For 2 recordings, a transcript separated by speaker was not available, so quotes come from the original automatic transcript and may lack speaker labels.","Not yet captured in this edition: a view on occupational cognitive demands as a reason to consider alternatives to first-line enzalutamide; a remark on abemaciclib’s mechanism and investigational status in metastatic hormone-sensitive prostate cancer; a view on metastasis-directed treatment, systemic therapy deferral, and uncertainty about safely stopping systemic treatment; a view on selecting patients for triplet therapy rather than standard doublet treatment in metastatic hormone-sensitive prostate cancer; a remark on selected-patient triplet evidence and continuing therapeutic need in high-risk metastatic hormone-sensitive prostate cancer; a question about de novo metastatic representation in evidence informing treatment intensification; a view on PSMA-targeted radioligand therapy as an emerging systemic option in metastatic hormone-sensitive prostate cancer; a view on cautious treatment interruption in hormone-sensitive disease because of comorbidities or severe side effects.","1 more clinician view in the sources used in this report is not yet captured as evidence in this edition.","126 statements in the sources reviewed for this edition are about other patients or topics, or only mention the trial, and are not counted.","Further source limits: 30 sources about other trials or topics are not included.","ClinicalTrials.gov first posted results for CYCLONE 3 on 27 June 2025. The cited commentary dates from October 2022 to September 2024 and predates those results; none of it discusses them. No separate results publication was identified in the sources reviewed for this edition. Protocol objectives and endpoints, and expectations expressed before that posting, must not be read as observed benefit or harm.","The public discussion located through trial names and identifiers may miss relevant unnamed discussion or differently transcribed references. The report does not represent all HCPs or all public discussion.","Individual ownership is uncertain for many podcast and video passages. Participation lists, program descriptions and familiar speaker labels do not establish who said those words.","Several episodes may include overlapping participants, and reposts or quoted posts do not establish additional independent HCP opinions.","Treatment preferences, approval statements, reimbursement experiences and guideline interpretations are historical as expressed in the sources, rather than current clinical or regulatory guidance.","Protocol and commentary descriptions differ on some eligibility and design details. Spoken thresholds and prior-docetaxel descriptions are preserved as statements, not silently substituted for the protocol.","Broader mHSPC practice discussions often include populations, alternatives or later treatment consequences not directly tested by CYCLONE 3; they do not establish abemaciclib benefit in a subgroup."]},"sources":{"cited_sources":{"by_channel":{"bluesky_thread":0,"linkedin_post":0,"other":0,"podcast":4,"publication":0,"registry":1,"regulatory":0,"x_thread":9,"x_video":0,"youtube":1},"by_evidence_role":{"commentary":14,"methods":1},"count":15,"evidence_window":{"end":"2024-09-16","start":"2022-10-21"},"retrieval_snapshot":"2026-11-15T18:28:06.642107Z","timeline":[{"count":1,"week":"2022-W42"},{"count":2,"week":"2023-W04"},{"count":1,"week":"2023-W11"},{"count":1,"week":"2023-W12"},{"count":1,"week":"2023-W18"},{"count":1,"week":"2023-W48"},{"count":1,"week":"2023-W51"},{"count":1,"week":"2024-W06"},{"count":1,"week":"2024-W08"},{"count":1,"week":"2024-W09"},{"count":2,"week":"2024-W17"},{"count":1,"week":"2024-W38"}],"undated_sources":1},"quote_policies":[{"id":"clinicaltrials:NCT05288166:methods","quote_policy":"short_quote_link_out"},{"id":"clinicaltrials:NCT05288166:results","quote_policy":"short_quote_link_out"},{"id":"clinicaltrials:NCT05288166:context","quote_policy":"short_quote_link_out"},{"id":"clinicaltrials:NCT05288166:protocol:1","quote_policy":"short_quote_link_out"},{"id":"clinicaltrials:NCT05288166:sap:2","quote_policy":"short_quote_link_out"},{"id":"openfda:be4bc0de-0fdc-4d46-8d25-be43c79e6a06:20260918","quote_policy":"short_quote_link_out"},{"id":"openfda:413c645e-074d-4276-b39a-d83521077602:20261026","quote_policy":"short_quote_link_out"},{"id":"mcp:podcast:567b85","quote_policy":"short_quote_link_out"},{"id":"mcp:podcast:b80d9c","quote_policy":"short_quote_link_out"},{"id":"mcp:podcast:e5bfc5","quote_policy":"short_quote_link_out"},{"id":"mcp:podcast:e7be4e","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1568600084207603712:d2f73657-290f-4c49-8bf2-14cc45040061","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1568614809981296641:df480e67-99bf-4fac-948f-d0f4cecee8bd","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1568904124460310528:01802ea6-5533-437d-bb48-bc08e05f5e1c","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1568981465983074304:e49fc878-4214-471f-9e74-40ee95bb82eb","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1569489342065786882:0966cb3e-e6fd-4481-b362-5bd049260818","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1576264340067401728:a8f78ce7-f9cb-44e3-a66b-b1a3a78877e5","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1583371062804238337:fccf476b-3177-4398-af7a-093d0969e6b4","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1605971551777701894:c77c9cee-3d98-4c8a-96ad-229e9d3f4c7f","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1617945414103142408:401f1f4a-d482-4977-aa06-f0420d0a18c2","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1617972209691275264:d9bf1784-8dee-47eb-b52d-8e036468cf82","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1625585742381518849:16186b3d-c21a-43f3-8099-9cdf9df29450","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1636079907645059075:ff01b25d-c4a0-4706-b13d-49638767d572","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1643690055897079828:76e2cc3d-c75c-41b5-a6f5-2f1afa15992d","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1725574150394159314:c95150d6-23f0-4ed4-9cba-1cf177f254ff","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1729546250339426413:83d0e4b6-5d4c-4c7a-bd9a-bf0de7c140fe","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1750239648037707879:9a6ceef3-dab9-4aa9-a6c8-a31efc395f23","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1754912773400887767:bb76ef4c-245a-45f3-a5c1-aca00ff16813","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1754962990929986014:9fb45987-cc3e-48f5-9f2b-2743f4dcb1a3","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1762983612490694716:44e8f390-3fdc-452a-b3b8-358f637bb648","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1770941042570768886:e0d0ceee-7e0f-4320-bb75-b0139544e02b","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1780363138686235134:cd5bfc4d-2599-4df6-a7d1-fd0b1bc642e8","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1783768481097273756:d9ede3f8-0f9b-47d7-8b44-fee508ce5b82","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1783773374210056316:b982b11d-f172-4436-9965-4791284f4f06","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1785266431371714757:c64c28f9-909f-490d-b2eb-5880abefdbcc","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1790872383160496489:f0aee67b-1bd6-4315-89ee-de6985b6b1fe","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1797001189294309735:e8236567-0172-4beb-816d-29d15bf7516d","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1800656847998800247:ced31b08-439a-497d-bf1a-47ca3242b946","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1811890872037851371:5d0abcf4-8128-4ef0-870c-e7042f275200","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1825638970841071882:e6abc668-d3e2-45d3-a636-a753bf89a124","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1835602083359109306:337377dd-b3ad-42bc-afed-ab1c1e3f7e7d","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1835686693086671161:879d8443-3f92-4659-8a88-b52cb1a4828d","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1836170857334423691:73430687-4e32-4699-96e6-ea917c083d8c","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1847042492174127331:f4058fd9-797c-45f0-80c4-4c7cd74684cb","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1856479683082141785:5fa3c020-9487-4b33-b9bf-b570411a620c","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1867351319322710431:fe6d7cca-ad02-4384-a1cc-3b6df6e529a5","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1879310115049820643:a9c6e6f2-b9eb-46b4-9818-2d0ca1cbf66c","quote_policy":"short_quote_link_out"},{"id":"mcp:youtube:EgXZz5A5eUk","quote_policy":"short_quote_link_out"}],"screened_sources":{"by_channel":{"bluesky_thread":0,"linkedin_post":0,"other":0,"podcast":4,"publication":0,"registry":0,"regulatory":0,"x_thread":36,"x_video":0,"youtube":1},"by_evidence_role":{"commentary":41},"count":41,"evidence_window":{"end":"2025-01-14","start":"2022-09-10"},"retrieval_snapshot":"2026-11-15T18:28:06.642107Z","timeline":[{"count":4,"week":"2022-W36"},{"count":1,"week":"2022-W37"},{"count":1,"week":"2022-W39"},{"count":1,"week":"2022-W42"},{"count":1,"week":"2022-W51"},{"count":2,"week":"2023-W04"},{"count":1,"week":"2023-W07"},{"count":1,"week":"2023-W11"},{"count":1,"week":"2023-W12"},{"count":1,"week":"2023-W14"},{"count":1,"week":"2023-W18"},{"count":1,"week":"2023-W46"},{"count":1,"week":"2023-W48"},{"count":1,"week":"2023-W51"},{"count":1,"week":"2024-W04"},{"count":2,"week":"2024-W06"},{"count":1,"week":"2024-W08"},{"count":2,"week":"2024-W09"},{"count":1,"week":"2024-W12"},{"count":1,"week":"2024-W16"},{"count":2,"week":"2024-W17"},{"count":1,"week":"2024-W18"},{"count":1,"week":"2024-W20"},{"count":1,"week":"2024-W22"},{"count":1,"week":"2024-W24"},{"count":1,"week":"2024-W28"},{"count":1,"week":"2024-W34"},{"count":3,"week":"2024-W38"},{"count":1,"week":"2024-W42"},{"count":1,"week":"2024-W46"},{"count":1,"week":"2024-W50"},{"count":1,"week":"2025-W03"}],"undated_sources":0},"statements_by_channel":{"bluesky_thread":0,"linkedin_post":0,"other":0,"podcast":187,"publication":0,"registry":8,"regulatory":0,"x_thread":12,"x_video":0,"youtube":11}},"taxonomy":{"biomarkers":{"reason":"No structured, checked-in biomarker mapping for this trial.","status":"unmapped"},"congresses":{"reason":"No congress places this trial yet.","status":"none"},"drugs":[{"brand_names":["Verzenio"],"label":"abemaciclib","slug":"abemaciclib"},{"brand_names":["Zytiga"],"label":"abiraterone acetate","slug":"abiraterone-acetate"},{"brand_names":["Cortan","Delta-Dome","Deltasone","Fernisone","Liquid Pred","Meticorten","Orasone","Paracort","Prednicen-M","Rayos","Servisone"],"label":"prednisone","slug":"prednisone"},{"brand_names":["Cortalone","Delta-Cortef","Fernisolone-P","Flo-Pred","Hydeltrasol","Meticortelone","Orapred","Pediapred","Prelone","Sterane"],"label":"prednisolone","slug":"prednisolone"}],"indications":[{"brand_names":{"reason":"Indication, not a drug.","status":"not_applicable"},"label":"Prostate cancer","slug":"prostate-cancer"},{"reason":"Unmapped registry condition: Neoplasm Metastasis","status":"unmapped"},{"reason":"Unmapped registry condition: Urogenital Neoplasms","status":"unmapped"},{"reason":"Unmapped registry condition: Physiological Effects of Drugs","status":"unmapped"},{"reason":"Unmapped registry condition: Antineoplastic Agents","status":"unmapped"},{"reason":"Unmapped registry condition: Antineoplastic Agents, Hormonal","status":"unmapped"},{"reason":"Unmapped registry condition: Androgens","status":"unmapped"},{"reason":"Unmapped registry condition: Hormones","status":"unmapped"},{"reason":"Unmapped registry condition: Hormones, Hormone Substitutes, and Hormone Antagonists","status":"unmapped"},{"reason":"Unmapped registry condition: Abiraterone Acetate","status":"unmapped"},{"reason":"Unmapped registry condition: Steroid Synthesis Inhibitors","status":"unmapped"},{"reason":"Unmapped registry condition: Cytochrome P-450","status":"unmapped"},{"reason":"Unmapped registry condition: Enzyme Inhibitors","status":"unmapped"},{"reason":"Unmapped registry condition: Prednisone","status":"unmapped"},{"reason":"Unmapped registry condition: Prednisolone","status":"unmapped"},{"reason":"Unmapped registry condition: Cyclin-Dependent Kinase 4","status":"unmapped"},{"reason":"Unmapped registry condition: Cyclin-Dependent Kinase 6","status":"unmapped"}],"line_of_therapy":{"reason":"No structured, checked-in line-of-therapy mapping for this trial.","status":"unmapped"},"therapeutic_area":["oncology"]},"trial":{"acronym":"CYCLONE 3","aliases":["CYCLONE 3","A Study of Abemaciclib (LY2835219) With Abiraterone in Men With Prostate Cancer That Has Spread to Other Parts of the Body and is Expected to Respond to Hormonal Treatment (Metastatic Hormone-Sensitive Prostate Cancer)","CYCLONE 3: A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study of Abemaciclib in Combination With Abiraterone Plus Prednisone in Men With High-Risk Metastatic Hormone-Sensitive Prostate Cancer"],"brief_title":"A Study of Abemaciclib (LY2835219) With Abiraterone in Men With Prostate Cancer That Has Spread to Other Parts of the Body and is Expected to Respond to Hormonal Treatment (Metastatic Hormone-Sensitive Prostate Cancer)","collaborators":{"reason":"Not present in the acquired registry snapshot.","status":"unavailable"},"conditions":["Prostatic Neoplasms","Neoplasm Metastasis","Urogenital Neoplasms","Physiological Effects of Drugs","Antineoplastic Agents","Antineoplastic Agents, Hormonal","Androgens","Hormones","Hormones, Hormone Substitutes, and Hormone Antagonists","Abiraterone Acetate","Steroid Synthesis Inhibitors","Cytochrome P-450","Enzyme Inhibitors","Prednisone","Prednisolone","Cyclin-Dependent Kinase 4","Cyclin-Dependent Kinase 6"],"display_condition":"high-risk metastatic hormone-sensitive prostate cancer","display_interventions":[["abemaciclib","abiraterone"]],"enrollment":{"count":925,"type":"ACTUAL"},"interventions":[{"name":"Abemaciclib","synonyms":["LY2835219"],"type":"DRUG"},{"name":"Abiraterone","synonyms":{"reason":"Not present in the acquired registry snapshot.","status":"unavailable"},"type":"DRUG"},{"name":"Prednisone or Prednisolone","synonyms":{"reason":"Not present in the acquired registry snapshot.","status":"unavailable"},"type":"DRUG"},{"name":"Placebo for Abemaciclib","synonyms":{"reason":"Not present in the acquired registry snapshot.","status":"unavailable"},"type":"DRUG"}],"nct_id":"NCT05288166","official_title":"CYCLONE 3: A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study of Abemaciclib in Combination With Abiraterone Plus Prednisone in Men With High-Risk Metastatic Hormone-Sensitive Prostate Cancer","overall_status":"ACTIVE_NOT_RECRUITING","phase":["PHASE3"],"primary_completion_date":{"date":"2024-02-15","type":"ACTUAL"},"primary_endpoints":[{"description":"The rPFS time is measured from the date of randomization to the earliest date of investigator determined radiographic disease progression (by objective radiographic disease assessment per response evaluation criteria in solid tumors (RECIST) version 1.1 for soft tissue AND/OR radionuclide bone scan using prostate cancer working group 3 -PCWG3 criteria for bone) or death from any cause, whichever occurs first.","measure":"Radiographic Progression-Free Survival (rPFS) Assessed by Investigator","timeFrame":"From Date of Randomization to Radiographic Disease Progression or Death from Any Cause (up to 22 months)"}],"registered_date":{"date":"2022-03-21","type":"ACTUAL"},"registry_last_updated":"2026-07-01","registry_url":"https://clinicaltrials.gov/study/NCT05288166","short_name":"CYCLONE 3","short_name_basis":"registry_acronym","sponsor":"Eli Lilly and Company","start_date":{"date":"2022-04-14","type":"ACTUAL"},"study_design":"interventional, randomized, parallel, phase3","study_ids":[{"id":"18448","type":"sponsor_study_id"},{"domain":"Eli Lilly and Company","id":"I3Y-MC-JPEG","type":"other"},{"domain":"EU Trial Number","id":"2022-500461-28-06","type":"other"}],"study_type":"INTERVENTIONAL"}}}